Evidence map›Paper›PMID 39508030›Full record

ArticleFrontiers in photonics2022

Prospects for Fluorescence Molecular

Mark Niedre

Abstract read
In one paragraph

Article in Frontiers in photonics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Two-color diffuseJournal of biomedical optics · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Near-infrared diffuse in vivo flow cytometry.Journal of biomedical optics · 2022
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Mark NiedreDepartment of Bioengineering, Northeastern University, Boston, MA, United States.

Funding

Circulating Red Blood Cell Based Nanosensors for Continuous, Real-Time Drug MonitoringR01EB024186 · NIBIB · NORTHEASTERN UNIVERSITY · PI CLARK, HEATHER A, NIEDRE, MARK JONATHAN · 2018 to 2021
$1.6M
Fluorescence Molecular In Vivo Liquid Biopsy of Circulating Tumor CellsR21CA246413 · NCI · NORTHEASTERN UNIVERSITY · PI NIEDRE, MARK JONATHAN · 2021 to 2022
$389k
NCI NIH HHS R21 CA246413NIBIB NIH HHS R01 EB024186
6 · The paper itself

Abstract

Our team recently developed "Diffuse in vivo Flow Cytometry" (DiFC) for detection and enumeration rare circulating tumor cells (CTCs) in mice with highly-scattered fluorescent light. We have used DiFC to study dissemination of CTCs in a number of mouse models of metastasis with fluorescent protein expressing cells. Because DiFC uses diffuse light and interrogates large blood vessels in relatively deep tissue, in principle it could be translated to larger limbs, species, and even humans clinically. In this perspective, we discuss the technical challenges of human translation of DiFC in the context of the current state of the technology, as well as potential strategies for labeling of CTCs with targeted fluorescent molecular probes. We also discuss potential advantages and disadvantages of DiFC as a clinical tool. In principle, DiFC could represent a powerful complementary technique (to liquid biopsy blood draws) for accurate and sensitive measurement of changes in CTC numbers over time.

Indexed as

circulating tumor cellsfluorescenceliquid biopsymetastasisoptical devices

Identifiers

PMID39508030
PMCPMC11540420

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.